TAG:
breast cancer test
In Florida, More Tests Added to UHC’s Decision-Support Program
By Joseph Burns | From the Volume XXV No. 1 – January 2, 2018 Issue
IN THE FIRST BROAD EXPANSION OF ITS pilot decision-support program for clinical lab testing in Florida, UnitedHealthcare (UHC) will add genetic and molecular tests, drug tests, and pathology procedures, among other assays starting in two months. On March 1, UHC will expand its labor…
Is New Cycle of Fraud Plaguing Lab Industry?
By Robert Michel | From the Volume XXII No. 12 – August 24, 2015 Issue
CEO SUMMARY: Taken collectively, the growing number of federal investigations of clinical lab companies and health insurer lawsuits against lab companies alleging fraudulent business practices signals a disturbing new trend for the lab industry. Although these allegations are lev…
More Genetic Counseling Leads to Fewer Lab Tests
By Joseph Burns | From the Volume XXI No. 17 – December 15, 2014 Issue
CEO SUMMARY: Cigna was the first national health insurer to require independent board-certified genetic counseling before approving coverage for certain genetic tests. Since launching this program in September 2013, the insurer has seen a 450% increase in genetic counseling for Cigna …
Eastern Canada’s Latest Lab Errors Get Attention
By Joseph Burns | From the Volume XXI No. 4 – March 17, 2014 Issue
CEO SUMMARY: Authorities for Eastern Health in Newfoundland and Labrador province in Canada are conducting a root cause analysis after finding discrepancies in breast cancer testing that affected nine patients. Health officials said these cases were discovered as a result of an improved q…
August 27, 2012 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
How big is the market for laboratory testing in China, with its 20,000 hospitals and population of 1.3 billion people? A new report estimates that the independent clinical laboratory industry in China currently generates about 2 billion Yuan Renminbi per year in revenue. This is equal to about US $31…
June 13, 2011 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVIII No. 8 – June 13, 2011 Issue
In coming weeks, Agendia, probably best known for its genetic breast cancer test, hopes to complete an initial public offering (IPO). Agendia is a company based in Amsterdam, The Netherlands with offices in Irvine, California. Its stock symbol will be “AGDX” and the shares will t…
Serious Problems Plague Newfoundland Laboratory
By Robert Michel | From the Volume XVII No. 5 – March 29, 2010 Issue
CEO SUMMARY: Newfoundland’s St. John laboratory was rocked by revelations in February that its cyclosporine testing was flawed, exposing patients to the harmful affects from inappropriately high doses of the immunosuppressant drug. Within weeks of this news, the Chief of Laboratory Medi…
Beckman Coulter, Olympus, LabCorp, Anthem, WellPoint, Medtox, University of Toronto
By Robert Michel | From the Volume XVII No. 3 – February 15, 2010 Issue
BECKMAN COULTER REPORTS EARNINGS THAT INCLUDE OLYMPUS THERE WAS A BIG JUMP in fourth quarter revenue at Beckman Coulter Inc., of Brea, California, which increased by 22% over the previous year, to $989.6 million. This number included $120.2 million in reven…
2009’s Top Ten Lab Stories Reflect Some Good, Bad
By Robert Michel | From the Volume XVI No. 17 – December 14, 2009 Issue
CEO SUMMARY: As the closing year of the first decade of the new century and the new millennium, 2009 brought neither disruption nor upheaval to the majority of laboratories in the United States. Rather, it was marked by at least two themes. One was how public disclosure of problems with l…
August 31, 2009 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVI No. 12 – August 31, 2009 Issue
These days, you hear plenty about Web 2.0 and how it is revolutionizing the way people use the Internet. Pathologist Keith Kaplan, M.D., at the Mayo Clinic uses the term “Pathology 2.0” to describe how use of Web 2.0 technology will similarly transform the anatomic pathology prof…
CURRENT ISSUE
Volume XXXII, No. 1 – January 6, 2025
The Dark Report examines how AI is being used to predict the outcomes of FDA LDT lawsuits. Also, this issue is Part Two of a series about boosting pathology compensation in different settings, including hospitals. Two experienced pathology consultants identify the most effective approaches when negotiating Part A pathology agreements with hospitals and health systems, along with how to use data to bolster these negotiations.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized
The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103
Email: info@darkreport.com
© 2025 The Dark Report. All rights reserved.